Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of MRSA infection: a health-care system perspective

von Dach, E., Morel, C. M., Murthy, A., Pagani, L., Macedo-Vinas, M., Olearo, F. and Harbarth, S. (2017) Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of MRSA infection: a health-care system perspective. Clinical Microbiology and Infection, 23 (9). pp. 659-666. ISSN 1198-743X

Preview

PDF - Accepted Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (12MB) | Preview

Abstract

To date few industry-independent studies were conducted to compare the relative costs and benefits of drugs to treat MRSA infection. We performed a stochastic cost-effectiveness analysis comparing two treatment strategies -- linezolid versus trimethoprim-sulfamethoxazole plus rifampicin -- for the treatment of MRSA infection.

Item Type:	Article
Official URL:	http://www.clinicalmicrobiologyandinfection.com/
Additional Information:	© 2017 The Authors © CC BY-NC-ND 4.0
Divisions:	Social Policy LSE Health
Subjects:	R Medicine > R Medicine (General) R Medicine > RA Public aspects of medicine
Date Deposited:	01 Mar 2017 18:15
Last Modified:	12 Dec 2024 01:26
URI:	http://eprints.lse.ac.uk/id/eprint/69613

Actions (login required)

View Item